Predictive Factor for Therapeutic Results after Intravenous Glucocorticoid Therapy in Thyroid-Associated Ophthalmopathy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives: Little has been known for factors predicting improvement of proptosis in patients with thyroid-associated ophthalmopathy (TAO) after intravenous (IV) glucocorticoid therapy. This study aimed to evaluate the efficacy of IV glucocorticoid therapy and to find factor predicting treatment outcomes in patients with TAO. Materials and Methods: Forty-two consecutive patients with TAO treated by IV glucocorticoid from 2000 to 2009 were retrospectively analyzed. They received IV methylprednisolone of 7.0 g over 18 weeks. Before and after treatment, patients underwent orbital CT for assessment of proptosis and extraocular muscle hypertrophy, and physical examination for clinical activity score (CAS). Results: Thirteen patients (31%) showed improvement in proptosis after therapy. High extraocular muscle diameter index was an independent predictor for improvement in proptosis (odds ratio=1.25, p=0.03). Smoking, age, gender and initial CAS did not predict improvement. Seven of 16 patients with initial CAS＜3 (43%) and 13 of 17 with initial CAS≥3 (77%) showed improvement in diplopia after treatment (p=0.002). Of patients with CAS≥3, patients with intermittent,inconstant and constant diplopia showed improvement in diplopia in 100%, 80% and 63%, respectively. Of patients with CAS＜3, patients showed improvement in 80%, 33% and 20%, respectively. Conclusion: Presence of extraocular muscle hypertrophy was the only factor predicting improvement in proptosis after IV glucocorticoid therapy. In patients with TAO, IV glucocorticoid therapy could be considered to improve proptosis when they present with increased extraocular muscle diameter, or to improve diplopia especially when they also have high initial CAS.
Abstract
Background and Objectives: Little has been known for factors predicting improvement of proptosis in patients with thyroid-associated ophthalmopathy (TAO) after intravenous (IV) glucocorticoid therapy. This study aimed to evaluate the efficacy of IV glucocorticoid therapy and to find factor predicting treatment outcomes in patients with TAO. Materials and Methods: Forty-two consecutive patients with TAO treated by IV glucocorticoid from 2000 to 2009 were retrospectively analyzed. They received IV methylprednisolone of 7.0 g over 18 weeks. Before and after treatment, patients underwent orbital CT for assessment of proptosis and extraocular muscle hypertrophy, and physical examination for clinical activity score (CAS). Results: Thirteen patients (31%) showed improvement in proptosis after therapy. High extraocular muscle diameter index was an independent predictor for improvement in proptosis (odds ratio=1.25, p=0.03). Smoking, age, gender and initial CAS did not predict improvement. Seven of 16 patients with initial CAS＜3 (43%) and 13 of 17 with initial CAS≥3 (77%) showed improvement in diplopia after treatment (p=0.002). Of patients with CAS≥3, patients with intermittent,inconstant and constant diplopia showed improvement in diplopia in 100%, 80% and 63%, respectively. Of patients with CAS＜3, patients showed improvement in 80%, 33% and 20%, respectively. Conclusion: Presence of extraocular muscle hypertrophy was the only factor predicting improvement in proptosis after IV glucocorticoid therapy. In patients with TAO, IV glucocorticoid therapy could be considered to improve proptosis when they present with increased extraocular muscle diameter, or to improve diplopia especially when they also have high initial CAS.
참고문헌 (24)
- Garrity JA, "Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment", Am J Ophthalmol, 142(1), pp.147~153 (2006)
- Bartalena L, "Clinical practice. Graves' ophthalmopathy", N Engl J Med, 360(10), pp.994~1001 (2009)
- Terwee CB, "Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL", Br J Ophthalmol, 82(7), pp.773~779 (1998)
- Perros P, "Natural history of thyroid associated ophthalmopathy", Clin Endocrinol, 42(1), pp.45~50 (1995)
- Dickinson AJ, "Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment", Clin Endocrinol, 55(3), pp.283~303 (2001)
- Bartalena L, "Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy", Thyroid, 18(3), pp.333~346 (2008)
- Mourits MP, "Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy", Clin Endocrinol, 47(1), pp.9~14 (1997)
- Kim IT, "Normal range of exophthalmos values on orbit computerized tomography in Koreans", Ophthalmologica, 215(3), pp.156~162 (2001)
- Nugent RA, "Graves orbitopathy: correlation of CT and clinical findings", Radiology, 177(3), pp.675~682 (1990)
- Sheikh M, "Normal measurement of orbital structures: implications for the assessment of Graves' ophthalmopathy", Australas Radiol, 51(3), pp.253~256 (2007)
- Ozgen A, "Quantitative CT of the orbit in Graves' disease", Br J Radiol, 72(860), pp.757~762 (1999)
- Bahn RS, "Graves' ophthalmopathy", N Engl J Med, 362(8), pp.726~738 (2010)
- Bahn RS, "Heufelder AE. Pathogenesis of Graves' ophthalmopathy", N Engl J Med, 329(20), pp.1468~1475 (1993)
- Garrity JA, "Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment", Am J Ophthalmol, 142, pp.147~153 (2006)
- Nagy EV, "Graves' ophthalmopathy: eye muscle involvement in patients with diplopia", Eur J Endocrinol, 142(6), pp.591~597 (2000)
- Smith TJ, "Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy", J Clin Endocrinol Metab, 87(1), pp.385~392 (2002)
- Stiebel-Kalish H, "Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis", J Clin Endocrinol Metab, 94(8), pp.2708~2716 (2009)
- Ohtsuka K, "Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy", Am J Ophthalmol, 135(3), pp.285~290 (2003)
- van Geest RJ, "Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study", Eur J Endocrinol, 158(2), pp.229~237 (2008)
- Marcocci C, "Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study", J Clin Endocrinol Metab, 86(8), pp.3562~3567 (2001)
- Kahaly GJ, "Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy", J Clin Endocrinol Metab, 90(9), pp.5234~5240 (2005)
- Gorman CA, "The measurement of change in Graves' ophthalmopathy", Thyroid, 8(6), pp.539~543 (1998)
- Lam AK, "Intra-observer and inter-observer variation of Hertel exophthalmometry", Ophthalmic Physiol Opt, 29(4), pp.472~476 (2009)
- Segni M, "Comparability of proptosis measurements by different techniques", Am J Ophthalmol, 133(6), pp.813~818 (2002)